1. Home
  2. GHI vs MDWD Comparison

GHI vs MDWD Comparison

Compare GHI & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GHI
  • MDWD
  • Stock Information
  • Founded
  • GHI 1998
  • MDWD 2000
  • Country
  • GHI United States
  • MDWD Israel
  • Employees
  • GHI N/A
  • MDWD N/A
  • Industry
  • GHI Finance: Consumer Services
  • MDWD Medicinal Chemicals and Botanical Products
  • Sector
  • GHI Finance
  • MDWD Health Care
  • Exchange
  • GHI Nasdaq
  • MDWD Nasdaq
  • Market Cap
  • GHI 254.1M
  • MDWD 208.2M
  • IPO Year
  • GHI N/A
  • MDWD 2014
  • Fundamental
  • Price
  • GHI $10.77
  • MDWD $17.84
  • Analyst Decision
  • GHI Strong Buy
  • MDWD Strong Buy
  • Analyst Count
  • GHI 4
  • MDWD 2
  • Target Price
  • GHI $14.88
  • MDWD $35.00
  • AVG Volume (30 Days)
  • GHI 51.9K
  • MDWD 159.5K
  • Earning Date
  • GHI 11-05-2025
  • MDWD 08-14-2025
  • Dividend Yield
  • GHI 13.72%
  • MDWD N/A
  • EPS Growth
  • GHI N/A
  • MDWD N/A
  • EPS
  • GHI N/A
  • MDWD N/A
  • Revenue
  • GHI $27,326,828.00
  • MDWD $19,858,000.00
  • Revenue This Year
  • GHI $228.92
  • MDWD $20.37
  • Revenue Next Year
  • GHI $4.27
  • MDWD $25.91
  • P/E Ratio
  • GHI N/A
  • MDWD N/A
  • Revenue Growth
  • GHI N/A
  • MDWD N/A
  • 52 Week Low
  • GHI $10.12
  • MDWD $14.14
  • 52 Week High
  • GHI $14.51
  • MDWD $22.51
  • Technical
  • Relative Strength Index (RSI)
  • GHI 48.31
  • MDWD 51.00
  • Support Level
  • GHI $10.65
  • MDWD $16.08
  • Resistance Level
  • GHI $10.88
  • MDWD $20.30
  • Average True Range (ATR)
  • GHI 0.21
  • MDWD 0.95
  • MACD
  • GHI 0.01
  • MDWD 0.26
  • Stochastic Oscillator
  • GHI 50.00
  • MDWD 41.71

About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests

Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: